Aldeyra Therapeutics remains a pre-revenue biotechnology entity heavily reliant on equity-based funding to sustain its clinical development pipeline. The company faces significant financial pressure as it navigates a path toward commercialization, with cumulat...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 7, 2026 | -$0.06+53.8% vs -$0.13 | — vs — |
Q1 2026 Feb 27, 2026 | -$0.11+21.4% vs -$0.14 | — vs $5M |
Q4 2025 Nov 5, 2025 | -$0.13+23.5% vs -$0.17 | — vs $24M |
Q3 2025 Aug 7, 2025 | -$0.16+23.8% vs -$0.21 | — vs — |
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis
Benchmark ALDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Aldeyra The (ALDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.35 | $81.43M | -2.41 | — | — | -58.73% | — | |
| $10.00 | $2.19B | -7.04 | -18.67% | -579.1% | -59.87% | — | |
| $0.56 | $10.83M | -0.17 | — | — | -187.45% | — | |
| $112.44 | $13.34B | 43.92 | 37.55% | 24.86% | 180.63% | — | |
| $49.85 | $5.97B | -15.15 | — | — | -160.19% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — |
Aldeyra The (ALDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Aldeyra The (ALDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 15, 2026·SEC
Jun 10, 2026·SEC
Get notified when ALDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aldeyra The (ALDX) stock FAQ — growth, dividends, profitability & financials explained
Aldeyra The (ALDX) reported a net loss of $23.1M for fiscal year 2025.
Aldeyra The (ALDX) has a return on equity (ROE) of -58.7%. Negative ROE indicates the company is unprofitable.
Aldeyra The (ALDX) had negative free cash flow of $22.0M in fiscal year 2025, likely due to heavy capital investments.
